{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:01:03Z","timestamp":1784329263803,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Plaque psoriasis is a common, long-lasting illness that affects the immune system and causes significant negative impacts on a patient\u2019s physical health, well-being, and ability to work effectively. Deucravacitinib (DEU) is the first oral medication used in the treatment of plaque psoriasis, a chronic skin condition that causes red, scaly patches on the skin. DEU is a type of medication called an oral Janus kinase (JAK) inhibitor, which works by blocking specific enzymes that play a role in the inflammation and immune response associated with psoriasis. Therefore, a quick, easy, novel, reliable, sensitive, and straightforward liquid chromatography-tandem mass spectrometry (LC-MS\/MS) approach was used to analyze DEU in plasma samples. The LC-MS\/MS method for the determination of DEU in human plasma was based on using trimethoprim as an internal standard (IS). The separation of DEU and IS was carried out via liquid\u2013liquid extraction (LLE). The extract was then subjected to the chromatographic system separation using the ACE-C18 column (4.6 \u00d7 100 mm, 5 \u00b5m). The mobile phase employed consisted of methanol and a solution of 2 mM ammonium formate (80:20 v\/v, respectively). The flow rate used was set at 0.9 mL min\u22121. The creative strategy was performed by running an ABSCIEX API 4000 mass spectrometer with an electron spray ionization source in multiple reaction monitoring (MRM) mode. The ion transitions m\/z 426.3 \u2192 358.2 were used for DEU quantitation, while the ion transitions m\/z 291.1 \u2192 261.1 were used for trimethoprim quantitation. The accuracy, precision, linearity, recovery, and selectivity of DEU were deemed acceptable when validated for a concentration range between 0.500 and 601.050 ng\/mL, utilizing a weighting factor of 1\/x2.<\/jats:p>","DOI":"10.3390\/molecules28145471","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T01:46:02Z","timestamp":1689644762000},"page":"5471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS\/MS: Application and Greenness Evaluation"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4520-8621","authenticated-orcid":false,"given":"Pottabattula","family":"Mahesh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis, Anurag University, Venkatapur, Ghatkesar Rd., Hyderabad 500088, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-3200","authenticated-orcid":false,"given":"M. Akiful","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, Anurag University, Venkatapur, Ghatkesar Rd., Hyderabad 500088, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher I.","family":"Salman","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1138-595X","authenticated-orcid":false,"given":"Tarek S.","family":"Belal","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, University of Alexandria, Alexandria 21521, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-1220","authenticated-orcid":false,"given":"Adel Ehab","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said 42511, Egypt"},{"name":"Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, Nizwa 616, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"El Deeb","sequence":"additional","affiliation":[{"name":"Institute of Medicinal and Pharmaceutical Chemistry, Technische Universitaet Braunschweig, Beethovenstr. 55, 38106 Braunschweig, Germany"},{"name":"Institute of Pharmacy, Freie Universit\u00e4t Berlin, Queen-Luise-Strasse 2 and 4, 14195 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100782","DOI":"10.1016\/j.ajps.2023.100782","article-title":"Water-responsive gel extends drug retention and facilitates skin penetration for curcumin topical delivery against psoriasis","volume":"18","author":"Yao","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clindermatol.2015.04.007","article-title":"Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?","volume":"33","author":"Omland","year":"2015","journal-title":"Clin. Dermatol."},{"key":"ref_4","first-page":"79","article-title":"A brief summary of clinical types of psoriasis","volume":"3","author":"Sarac","year":"2016","journal-title":"North. Clin. Istanb."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","article-title":"Immunopathogenic mechanisms in psoriasis","volume":"135","author":"Gudjonsson","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2340\/0001555562229236","article-title":"Psoriasis in monozygotic twins: Variations in expression in individuals with identical genetic constitution","volume":"62","author":"Brandrup","year":"1982","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.14246","article-title":"Review of safety and efficacy of approved systemic psoriasis therapies","volume":"58","author":"Kaushik","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/BTT.S252578","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the treatment of psoriatic disease","volume":"23","author":"Puig","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/cpdd.1056","article-title":"Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects","volume":"11","author":"Chimalakonda","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_18","unstructured":"Committee for Human Medicinal Products (2023, January 26). ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms. Proceedings of the International Conference on Harmonization, Geneva, Switzerland."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"El-Hela, A.A., Bakr, M.S.A., Hegazy, M.M., Dahab, M.A., Elmaaty, A.A., Ibrahim, A.E., El Deeb, S., and Abbass, H.S. (2023). Phytochemical Characterization of Pterocephalus frutescens with In-Silico Evaluation as Chemotherapeutic Medicine and Oral Pharmacokinetics Prediction Study. Sci. Pharm., 91.","DOI":"10.3390\/scipharm91010007"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hegazy, M.M., Afifi, W.M., Metwaly, A.M., Radwan, M.M., Abd-Elraouf, M., Mehany, A.B.M., Ahmed, E., Enany, S., Ezzeldin, S., and Ibrahim, A.E. (2022). Antitrypanosomal, Antitopoisomerase-I, and Cytotoxic Biological Evaluation of Some African Plants Belonging to Crassulaceae; Chemical Profiling of Extract Using UHPLC\/QTOF-MS\/MS. Molecules, 27.","DOI":"10.3390\/molecules27248809"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"119657","DOI":"10.1016\/j.molliq.2022.119657","article-title":"Hansen solubility parameters and green nanocarrier based removal of trimethoprim from contaminated aqueous solution","volume":"361","author":"Afzal","year":"2022","journal-title":"J. Mol. Liq."},{"key":"ref_22","unstructured":"(2023, June 18). DrugBank Release, Version 5.1.9; 2022. Available online: https:\/\/www.drugbank.ca."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sharaf, Y.A., Ibrahim, A.E., El Deeb, S., and Sayed, R.A. (2023). Green Chemometric Determination of Cefotaxime Sodium in the Presence of Its Degradation Impurities Using Different Multivariate Data Processing Tools; GAPI and AGREE Greenness Evaluation. Molecules, 28.","DOI":"10.3390\/molecules28052187"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113466","DOI":"10.1016\/j.jpba.2020.113466","article-title":"Bioanalytical method development and validation of a liquid chromatography-tandem mass spectrometry method for determination of \u03b2-lapachone in human plasma","volume":"188","author":"Putnam","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104017","DOI":"10.1016\/j.microc.2019.104017","article-title":"A validated LC-MS\/MS bioanalytical method for the simultaneous determination of dapagliflozin or saxagliptin with metformin in human plasma","volume":"149","author":"Hashem","year":"2019","journal-title":"Microchem. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40543-020-00219-5","article-title":"Development and validation of an LC-MS\/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies","volume":"11","author":"Chae","year":"2020","journal-title":"J. Anal. Sci. Technol."},{"key":"ref_27","unstructured":"(2021). United States Pharmacopoeia USP 43-NF 38, United States Pharmacopeia."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1021\/ac5018265","article-title":"Selecting the correct weighting factors for linear and quadratic calibration curves with least-squares regression algorithm in bioanalytical LC-MS\/MS assays and impacts of using incorrect weighting factors on curve stability, data quality, and assay performance","volume":"86","author":"Gu","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2300005","DOI":"10.1002\/ardp.202300005","article-title":"Zinc(II) complexation strategy for ultra-sensitive fluorimetric estimation of molnupiravir: Applications and greenness evaluation","volume":"356","author":"Salman","year":"2023","journal-title":"Arch. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","article-title":"Analytical Eco-Scale for assessing the greenness of analytical procedures","volume":"37","author":"Migaszewski","year":"2012","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","article-title":"A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index","volume":"181","year":"2018","journal-title":"Talanta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","article-title":"AGREE\u2014Analytical GREEnness Metric Approach and Software","volume":"92","author":"Wojnowski","year":"2020","journal-title":"Anal. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116223","DOI":"10.1016\/j.trac.2021.116223","article-title":"White Analytical Chemistry: An approach to reconcile the principles of Green Analytical Chemistry and functionality","volume":"138","author":"Nowak","year":"2021","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1021\/acs.analchem.9b01872","article-title":"What color is your method? Adaptation of the RGB additive color model to analytical method evaluation","volume":"91","author":"Nowak","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.trac.2019.06.015","article-title":"A new tool for evaluating and\/or selecting analytical methods: Summarizing the information in a hexagon","volume":"118","author":"Sancho","year":"2019","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1007\/s00216-021-03469-3","article-title":"Determination of six drugs used for treatment of common cold by micellar liquid chromatography","volume":"413","author":"Ibrahim","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4155\/bio.13.298","article-title":"New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: Chromatographic methods and ISR","volume":"6","author":"Zimmer","year":"2014","journal-title":"Bioanalysis"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Salman, B.I. (2023). A Novel Design Eco-friendly Microwave-assisted Cu\u2013N@ CQDs Sensor for the Quantification of Eravacycline via Spectrofluorimetric Method; Application to Greenness Assessments, Dosage Form and Biological Samples. J. Fluoresc., 1\u201310.","DOI":"10.1007\/s10895-023-03190-7"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/14\/5471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:13:38Z","timestamp":1760127218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/14\/5471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":38,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["molecules28145471"],"URL":"https:\/\/doi.org\/10.3390\/molecules28145471","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}